Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.42 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6709111 | 0.98 | NCF1 (0.46) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL1108993 | 0.91 | NCF1 (0.43) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL2558996 | 0.91 | NCF1 (0.43) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| Hydrochloric Acid SCHEMBL18980447 | 0.89 | NCF1 (0.41) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL12881610 | 0.89 | ALDH1A1 (0.46) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| Acetic Acid SCHEMBL7474512 | 0.87 | NCF1 (0.40) | NCF1SLC6A1GABRA5GABRB2SLC6A12 | |
| SCHEMBL13621150 | 0.83 | NCF1 (0.45) | NCF1GNAI3GNAO1GNAI1ITGB3 | |
| SCHEMBL10268818 | 0.82 | NCF1 (0.48) | NCF1GNAI3GNAO1GNAI1ALDH1A1 | |
| SCHEMBL2128921 | 0.80 | NCF1 (0.52) | NCF1GNAI3GNAO1GNAI1CACNA2D1 | |
| SCHEMBL11077478 | 0.80 | NCF1 (0.46) | NCF1GNAI3GNAO1GNAI1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 417 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0567967-B1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | THOMAE GMBH DR K (DE) | 1996-07-10 | — | — | EP | claimed |
| CN-122036736-A | Pyrrolo [2,3-d ] pyrimidine derivative, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-3801553-B1 | PRODRUGS OF FULVESTRANT | KASHIV BIOSCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4704907-A2 | LIPIDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND METHODS OF DELIVERING ACTIVE PHARMACEUTICAL INGREDIENTS | Nitto Denko Corporation (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | BIOCRYST PHARMACEUTICALS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2025098509-A1 | PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |
| EP-0085899-B1 | PYRIDOBENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1986-10-29 | — | — | EP | disclosed |
| US-4567178-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1986-01-28 | — | — | US | disclosed |
| EP-0085892-B1 | SUBSTITUTED BENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-12-18 | — | — | EP | disclosed |
| US-4447434-A | ANTIULCER, ANTISECRETORY, OR ANTICHOLINERGIC AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-05-08 | — | — | US | disclosed |
| US-4424225-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| US-4424226-A | ANTIULCER AGENTS | DR. KARL THOMAE GMBH (DE) | 1984-01-03 | — | — | US | disclosed |
| EP-0086982-A1 | Substituted thienobenzodiazepinones, process for preparing them and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | disclosed |
| EP-0085899-A2 | Pyridobenzodiazepinones, process for their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | NCF1 517/4885SLC6A1 2265/4885GABRA5 3789/4885 |
| US-12485109-B2 | Pyrrolo 12.3-dipyrimidine compounds and analogues thereof | C5, DPYD, C9 | NCF1 705/4885SLC6A1 3446/4885GABRA5 4050/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | NCF1 2176/4885SLC6A1 1654/4885GABRA5 4857/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | NCF1 450/4885SLC6A1 2924/4885GABRA5 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.